Claris Bio is at the forefront of developing innovative therapies for corneal diseases, focusing on unmet medical needs through a robust scientific approach. The company is pioneering the use of recombinant human deleted hepatocyte growth factor (dHGF) to enhance corneal healing and improve patient outcomes. This molecule is designed to accelerate wound healing, reduce scarring, and support nerve growth, making it particularly beneficial for conditions such as neurotrophic keratitis. Claris's dHGF therapy, known as CSB-001, is administered topically and has shown greater efficacy than existing treatments in clinical trials, demonstrating its potential to restore corneal integrity and transparency following various injuries and diseases.

The cornea plays a critical role in vision, and any disruption to its structure can lead to significant visual impairment. Claris Bio's research highlights the importance of the corneal layers and their functions, emphasizing the need for effective treatments for conditions that compromise corneal health. The company’s approach combines a deep understanding of corneal biology with innovative therapeutic strategies, aiming to address the challenges posed by corneal scarring and other sight-threatening conditions. Through ongoing clinical trials, Claris is committed to validating the effectiveness of its therapies and ultimately improving the quality of life for patients affected by corneal diseases.

United States

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

Claris Bio

Company Details